Solve Therapeutics, a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for solid tumor malignancies, has raised $120 million in an oversubscribed and upsized financing to accelerate the development of its clinical pipeline and proprietary CloakLink linker platform. The round was led by Yosemite, with participation from Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co., and SymBiosis, and existing investors Alexandria Venture In...